Drug
Dasatinib 100 MG
Dasatinib 100 MG is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_2
2
50%
Ph phase_4
1
25%
Phase Distribution
0
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 4Post-market surveillance
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(1)
Other(1)
Detailed Status
Recruiting1
Completed1
Not yet recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 22 (66.7%)
Phase 41 (33.3%)
Trials by Status
recruiting125%
completed125%
not_yet_recruiting125%
unknown125%
Recent Activity
1 active trials
Showing 4 of 4
recruitingphase_2
Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects
NCT05653258
not_yet_recruitingphase_4
Bioequivalence Studies of Dasatinib 100 Mg
NCT05944783
unknown
Early Conversion of Dasatinib in CML-CP Patients
NCT04136015
completedphase_2
Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer
NCT00371345
Clinical Trials (4)
Showing 4 of 4 trials
NCT05653258Phase 2
Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects
NCT05944783Phase 4
Bioequivalence Studies of Dasatinib 100 Mg
NCT04136015
Early Conversion of Dasatinib in CML-CP Patients
NCT00371345Phase 2
Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4